Plus Therapeutics Inc PSTV.OQ PSTV.O is expected to show a rise in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2024
The Austin Texas-based company is expected to report a 48.9% increase in revenue to $1.955 million from $1.31 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Plus Therapeutics Inc is for a loss of 39 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Plus Therapeutics Inc is $9.00, above its last closing price of $0.68.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.51 | -0.56 | -0.37 | Beat | 34.2 |
Jun. 30 2024 | -0.46 | -0.53 | -0.56 | Missed | -5.7 |
Mar. 31 2024 | -1.08 | -1.09 | -0.75 | Beat | 31.2 |
Dec. 31 2023 | -0.83 | -1.07 | -0.84 | Beat | 21.7 |
Sep. 30 2023 | -1.02 | -1.12 | -1.00 | Beat | 10.9 |
Jun. 30 2023 | -1.93 | -1.91 | -0.59 | Beat | 69.2 |
Mar. 31 2023 | -1.91 | -1.90 | -2.10 | Missed | -10.5 |
Dec. 31 2022 | -1.50 | -1.80 | -3.30 | Missed | -83.3 |
This summary was machine generated February 28 at 15:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。